Rakuten Medical Commences Global P-III (ECLIPSE) Study of ASP-1929 Plus Keytruda as a 1L Treatment of Recurrent Head and Neck Cancer
Shots:
- The company has begun P-III (ECLIPSE) trial of ASP-1929 (photoimmunotherapy) + Keytruda for HNSCC, with first patient treated at a site across the US. Recruitment is underway in Japan, Taiwan & other regions
- This global study aims at assessing safety & efficacy of ASP-1929 + Keytruda vs Keytruda-based SoC as a 1L treatment of patients (n=~400) with locoregional recurrent HNSCC without distant metastases. The 1EP includes OS & 2EPs are CRR & ORR
- The P-III trial was based on interim results (as of Aug 2023) from HNSCC arm (n=19) of prior P-Ib/II study, showing a 24mos. survival rate of 52.4% with mOS not reached & a tolerable safety profile
Ref: Rakuten Medical | Image: Rakuten Medical
Related News:- Rakuten Medical Highlights the Preclinical Results of RM-0256 at JCA 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
